for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ROHTO PHARMACEUTICAL CO., LTD.

4527.T

Latest Trade

3,405.00JPY

Change

25.00(+0.74%)

Volume

199,000

Today's Range

3,395.00

 - 

3,440.00

52 Week Range

2,508.00

 - 

3,535.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
3,380.00
Open
3,435.00
Volume
199,000
3M AVG Volume
5.73
Today's High
3,440.00
Today's Low
3,395.00
52 Week High
3,535.00
52 Week Low
2,508.00
Shares Out (MIL)
114.07
Market Cap (MIL)
399,141.30
Forward P/E
29.35
Dividend (Yield %)
0.74

Next Event

Q3 2020 Rohto Pharmaceutical Co Ltd Earnings Release

Latest Developments

More

Shionogi signs license agreement with Rohto Pharmaceutical

Rohto Pharmaceutical appoints president

Rohto Pharmaceutical says decease of president

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ROHTO PHARMACEUTICAL CO., LTD.

ROHTO PHARMACEUTICAL CO., LTD. is a Japan-based company principally engaged in the health and beauty care area. The Company primarily provides eye care-related products, including eye drops and eye lotions; skin care-related products, including dermatological preparations, lip balms, sunscreens and functional cosmetics; oral medication and food-related products, including digestive medicines, Chinese herbal medicines and supplements, as well as extracorporeal test drugs and other products. The Company operates its business in domestic market and overseas markets, including Europe, Asia and America.

Industry

Biotechnology & Drugs

Contact Info

1-8-1, Tatsumi-Nishi, Ikuno-ku

+81.6.67581231

https://www.rohto.co.jp/

Executive Leadership

Kunio Yamada

Chairman of the Board, President, Representative Director

Shinichi Kunisaki

Director of Business Strategy Promotion Unit, President of Subsidiary, Director

Lekh Raj Juneja

Vice President, Chief Health Officer, Director

Masaya Saito

Vice President, President of Subsidiary, Director

Yoichi Kambara

Managing Director

Key Stats

2.33 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.2K

2018

0.2K

2019

0.2K

2020(E)

0.2K
EPS (JPY)

2017

87.950

2018

81.550

2019

86.000

2020(E)

116.880
Price To Earnings (TTM)
39.52
Price To Sales (TTM)
2.14
Price To Book (MRQ)
2.88
Price To Cash Flow (TTM)
24.47
Total Debt To Equity (MRQ)
2.34
LT Debt To Equity (MRQ)
1.06
Return on Investment (TTM)
6.90
Return on Equity (TTM)
4.86

Latest News

Latest News

BRIEF-Rohto Pharmaceutical signs license agreement with Japan Tobacco

* Says it signed license agreement with Japan Tobacco Inc , regarding the exclusive rights to develop and commercialize JTE-052, which is used for disease treatment in the field of ophthalmology, in Japan

BRIEF-Sastasundar Ventures announces alliance With Rohto Pharmaceutical Co.

* Announces a capital and business alliance with Rohto Pharmaceutical Co.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up